Spectrum Pharmaceuticals, Inc.

NASDAQ:SPPI   11:19:23 AM EDT
2.95
-0.13 (-4.22%)
Products, Regulatory

Spectrum Pharmaceuticals Presents Results In HER2 Exon 20 Insertion Mutations From Cohort 2 Of The Poziotinib Zenith20 Clinical Trial

Published: 09/18/2020 11:21 GMT
Spectrum Pharmaceuticals, Inc. (SPPI) - Spectrum Pharmaceuticals Presents Results in Her2 Exon 20 Insertion Mutations From Cohort 2 of the Poziotinib Zenith20 Clinical Trial.
Spectrum Pharmaceuticals Inc - Phase 2 Clinical Trials Had 13 Patients With Treatment-related Serious Adverse Events.
Spectrum Pharmaceuticals Inc - in Phase 2 Clinical Trials, 11 Patients Permanently Discontinued Due to Adverse Events.
Spectrum Pharmaceuticals Inc - Requested Meeting With U.S. FDA to Discuss Data and Its Plans for a NDA Submission.
Spectrum Pharmaceuticals Inc - Top Line Results From Cohort 3 Are Expected by End of Year.